Table 4. Antifungal susceptibility data for first Candida auris isolates from 51 clinical cases, New York, USA, 2013–2017*.
| Antifungal | Tentative resistance breakpoint (16) | MIC50† | MIC range† | No. (%) resistant |
|---|---|---|---|---|
| Fluconazole | >32 | >256 | 8.00 to >256 | 50 (98) |
| Itraconazole | NA | 0.500 | 0.25–1.00 | NA |
| Voriconazole | NA | 2.000 | 0.50–4.00 | NA |
| Posaconazole | NA | 0.250 | 0.12–0.50 | NA |
| Isavuconazole | NA | 0.500 | 0.25–2.00 | NA |
| Caspofungin | >2 | 0.060 | 0.03–0.25 | 0 |
| Micafungin | >4 | 0.120 | 0.06–0.25 | 0 |
| Anidulafungin | >4 | 0.250 | 0.12–0.50 | 0 |
| Amphotericin B | >2 | 1.500 | 0.50–4.00 | 15 (29) |
| Flucytosine | NA | 0.125 | 0.125–0.25 | NA |
*NA, not available. †MICs for azoles and echinocandins are defined as the lowest drug concentration that caused 50% growth inhibition compared with the drug-free controls; MICs for amphotericin B and flucytosine are defined as the lowest concentration at which there was 100% growth inhibition. MIC50 was defined as the MIC at which >50% of the isolates of C. auris tested were inhibited.